ONL Therapeutics, Inc. — Department of Health and Human Services SBIR Phase II: NEI

Description

DESCRIPTION provided by applicant Death of photoreceptor cells is a consequence of many acute as well as chronic retinal diseases which lead to severe vision loss in patients If photoreceptors could be helped to survive the period of disease the visual outcomes for patients would be significantly better Retinal degenerative disease and injury are among the leading causes of irreversible vision loss and blindness in the United States and the developed world affecting hundreds of thousands of people every year and resulting in billions of dollars in added healthcare costs and lost productivity A problem limiting the efficacy of current treatments is that currently there are no interventions that can specifically prevent photoreceptor cell death therefore a safe potent photoreceptor protectant would provide a significant visual benefit to hundreds of thousands of people every year ONL Therapeutics is developing a product candidate a novel small peptide inhibitor of the FAS receptor ONL for peri operative adjunctive use in patients with acute retinal detachment an orphan indication with the goal of preventing photoreceptor cell death until definitive surgical repair can occur This acute indication provides a rapid development pathway that will lay the groundwork for future expansion of ONL development for chronic indications such as age related macular degeneration The product for acute retinal detachment will be a prescription drug for single dose intravitreal injection an established route of administration in ophthalmology Upon completion of this SBIR Phase II study ONL Therapeutics will have tested and validated the hypothesis that a safe and effective formulation for intravitreal injection of ONL can be developed for use in human clinical trials We will demonstrate that Intravitreal injection of ONL is safe and results in no significant ocular or systemic toxicity Pharmaceutical grade ONL for use in clinical trials can be produced and A Phase clinical trial can be designed to test the safety and efficacy of ONL in humans The work presented in this Phase II is the next step required for the commercialization of ONL and the results obtained will allow for finalization of the IND package required to begin clinical trials for the ue of ONL as an adjunctive treatment in patients with retinal detachments PUBLIC HEALTH RELEVANCE Diseases of the retina are a leading cause of irreversible blindness in the United States and result in tremendous social and economic impact on patients and society ONL Therapeutics LLC is dedicated to the development of a novel therapeutic agent that will prevent photoreceptor cell death during retinal disease Successful development of our lead product ONL a small peptide antagonist of the FAS receptor would result in the first photoreceptor neuroprotective agent available to physicians to improve visual outcomes and reduce blindness in patients